A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease

Trial Profile

A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs BIIB 054 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 26 Apr 2017 Planned End Date changed from 9 Aug 2017 to 7 Sep 2017.
    • 26 Apr 2017 Planned primary completion date changed from 9 Aug 2017 to 7 Sep 2017.
    • 28 Mar 2017 Data will be presented at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2017, according to a Biogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top